KB Medical raised CHF 2.5MM (~US $2.51MM) in a Series B Financing. Funds will support FDA approval and upgrade validations for the AQrate™ Robotic Assistance System V 1.2 for spinal surgery.
The company’s first product has completed clinical trials in spinal fusion on 24 patients and received CE Mark approval in 2Q16. Restricted launch will begin in 2017.
Additional functionality to be added to AQrate includes proprietary anti-skiving technology.
Sources: KB Medical SA; ORTHOWORLD Inc.
KB Medical raised CHF 2.5MM (~US $2.51MM) in a Series B Financing. Funds will support FDA approval and upgrade validations for the AQrate™ Robotic Assistance System V 1.2 for spinal surgery.
The company's first product has completed clinical trials in...
KB Medical raised CHF 2.5MM (~US $2.51MM) in a Series B Financing. Funds will support FDA approval and upgrade validations for the AQrate™ Robotic Assistance System V 1.2 for spinal surgery.
The company’s first product has completed clinical trials in spinal fusion on 24 patients and received CE Mark approval in 2Q16. Restricted launch will begin in 2017.
Additional functionality to be added to AQrate includes proprietary anti-skiving technology.
Sources: KB Medical SA; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
